A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children

British Journal of Haematology
Désirée CaselliMaurizio Aricò

Abstract

Given that the rationale for empirical antifungal therapy in neutropenic children is limited and based on adult patient data, we performed a prospective, randomized, controlled trial that evaluated 110 neutropenic children with persistent fever. Those at high risk for invasive fungal infections (IFI) received caspofungin (Arm C) or liposomal amphotericinB (Arm B); those with a lower risk were randomized to receive Arm B, C, or no antifungal treatment (Arm A). Complete response to empirical antifungal therapy was achieved in 90/104 patients (86·5%): 48/56 at high risk (85·7%) [88·0% in Arm B; 83·9% in Arm C (P = 0·72)], and 42/48 at low risk (87·5%) [87·5% in control Arm A, 80·0% Arm B, 94·1% Arm C; (P = 0·41)]. None of the variables tested by multiple logistic regression analysis showed a significant effect on the probability to achieve complete response. IFI was diagnosed in nine patients (8·2%, 95% confidence interval, 3·8-15·0). This randomized controlled study showed that empirical antifungal therapy was of no advantage in terms of survival without fever and IFI in patients aged <18 years and defined with low risk of IFI. Higher risk patients, including those with relapsed cancer, appear to be the target for empirical antif...Continue Reading

References

Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AbbasiP M Flynn
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GaynonH N Sather
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Mar 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Aug 6, 2002·Controlled Clinical Trials·Boris Freidlin, Edward L Korn
Apr 18, 2003·The New England Journal of Medicine·Greg S MartinMarc Moss
Mar 8, 2005·Journal of Pediatric Hematology/oncology·Galit P RosenTheodore B Moore
Apr 9, 2005·The Pediatric Infectious Disease Journal·William J Steinbach
Jun 29, 2006·The Pediatric Infectious Disease Journal·Elio CastagnolaMario R Rossi
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter BaderUNKNOWN ALL-REZ BFM Study Group
Mar 14, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Catherine CordonnierMichaël Schwarzinger
Jul 9, 2009·Bone Marrow Transplantation·P LjungmanUNKNOWN European Group for Blood and Marrow Transplantation
Jan 5, 2011·The Journal of Antimicrobial Chemotherapy·Livio PaganoNicole Blijlevens

❮ Previous
Next ❯

Citations

Mar 2, 2013·Pediatric Blood & Cancer·Parth S MehtaUNKNOWN Working Group on Essential Medicines of the Pediatric Oncology in Developing Countries committee of SIOP
Oct 29, 2014·Mycoses·Athanasios TragiannidisAndreas H Groll
Jul 2, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas F PattersonJohn E Bennett
May 2, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas LehrnbecherLillian Sung
Mar 13, 2014·The Pediatric Infectious Disease Journal·David F BesElvira Arrizurieta
Sep 5, 2014·The Cochrane Database of Systematic Reviews·Peter C Gøtzsche, Helle Krogh Johansen
Mar 30, 2018·The Pediatric Infectious Disease Journal·Magdalini TsekouraEmmanuel Roilides
Nov 22, 2018·Current Opinion in Pediatrics·Thomas Lehrnbecher
Jun 22, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andreas H GrollRoger J M Brüggemann
Jul 6, 2020·British Journal of Haematology·Andreas MerykRoman Crazzolara
Feb 14, 2019·Journal of Fungi·Savvas PapachristouEmmanuel Roilides

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.